Nanozyme immunopharmacology in rheumatoid arthritis: catalytic regulation of the synovial lesion microenvironment, evidence attribution, and translational barriers
Rheumatoid arthritis (RA) synovial lesions are sustained by interacting redox, immune, metabolic, and osteoimmune abnormalities. Nanozymes offer a means of modifying these microenvironmental processes, but the therapeutic activity of a complete formulation should not be equated with an independently established catalytic contribution. This critical narrative review organizes RA-related nanozyme research by pathological axis, treatment mode, and evidence maturity. An author-defined three-tier framework distinguishes animal therapeutic evidence with validated catalytic attribution from formulation-level efficacy and mechanistic or cross-disease observations. None of the representative studies appraised here establishes the complete Type A evidence chain under the stated criteria. Antioxidant and immunomodulatory activity, together with structural protection in selected experiments, supports further investigation of these platforms; however, drug delivery, targeting, material degradation, and externally applied energy frequently complicate causal interpretation. NET-directed interventions illustrate an additional distinction between suppressing trap formation, modifying neutrophil fate, and degrading pre-existing traps. Translational limitations include uncertain catalytic performance in synovial fluid, incomplete exposure and clearance measurements, limited repeated-dose safety evaluation, and heterogeneous comparisons with established antirheumatic therapies. Future studies should prioritize disease-relevant catalytic assays, validated attribution controls, treatment of established arthritis, structural and functional outcomes, and formulation-specific safety. These requirements define a research agenda rather than evidence of clinical readiness.
Authors
- Renli Deng (ORCID: https://orcid.org/0009-0008-7879-2139)
- Huijuan Su
- Weiju Liao
- Xingzhen Huang
- Ziyu Tang
- Xiaolian Chen
- Dingling Liang
Institutions
- Guangxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fphar.2026.1930216
- Primary Topic
- Advanced Nanomaterials in Catalysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Guangxi Medical University